Fig. 1.

Event rates (a) and hazard ratios (or relative risk for dabigatran) (b) for stroke or systemic embolism in patients ≥ 75 years of age in the four trials comparing non-vitamin K oral anticoagulants to vitamin K antagonist for stroke prevention in atrial fibrillation. HR, hazard ratio; NOAC, non-vitamin K oral anticoagulants; RR, relative risk; SSE, stroke or systemic embolism; VKA, vitamin K antagonist. Definition of major bleeding according to study criteria as well as dosing regimens is given for all studies in Table 1